On March 27, Cansino Biologics Inc(688185) released the 2021 annual report. During the reporting period, the company achieved an operating revenue of 4.3 billion yuan and a net profit of 1.914 billion yuan. In 2021, the company's R & D investment reached 905 million yuan, with a year-on-year increase of 111.14%. It plans to distribute a cash dividend of 8 yuan (including tax) for every 10 shares to all shareholders of the company, with a total cash dividend of about 198 million yuan (including tax).
At the same time of the annual report, Cansino Biologics Inc(688185) also announced that due to the first profit, the company's A-share abbreviation will cancel the special mark u on March 29, 2022 and change from " Cansino Biologics Inc(688185) -u" to " Cansino Biologics Inc(688185) ", which is also the first Biotechnology company to successfully "pick u" on the science and innovation board.
Cansino Biologics Inc(688185) was listed on the main board of the Hong Kong Stock Exchange in March 2019 and landed on the sci-tech innovation board in August 2020, becoming the first "a + H" vaccine stock since the opening of the sci-tech innovation board. In 2021, Cansino Biologics Inc(688185) bio New Coronavirus vaccine (5 adenovirus vector) was developed by third generation vaccine technology, and it was granted emergency application authorization or conditional approval by many other countries in China. One shot of covid-19 vaccine can stimulate significant cellular and humoral immunity and provide dual protection. In addition, keweisha also has the characteristics of long-term stable storage and transportation from 2 to 8, which greatly reduces the management cost of vaccination sites, reduces the burden of areas with shortage of medical resources or underdeveloped transportation, provides convenience for residents in remote areas, and helps the global fight against covid-19 pneumonia. Vaccination with Cansino Biologics Inc(688185) biological adenovirus vector covid-19 vaccine has good safety and immunogenicity, especially for vulnerable populations such as the elderly, which can provide stronger immune protection.
The company has also developed a global innovative inhalation recombinant New Coronavirus vaccine (type 5 adenovirus vector), which is based on the company's viral vector technology and is further developed by the company's research and development through respiratory mucosal immunization technology. Aerosol inhalation is used to atomized the vaccine into tiny particles, and through the oral inhalation into the respiratory tract and lungs, it can stimulate mucosal immune response. This mode of immunity cannot be brought about by intramuscular injection, which provides additional protection in respiratory mucosal tissue. The establishment of mucosal immunity in respiratory mucosa enables memory B cells and memory T cells distributed in respiratory mucosa to encounter pathogens earlier than systemic memory cells. Therefore, it can inhibit virus replication and reduce virus transmission faster. In March 2021, the company obtained the clinical approval of the product and has completed phase I and phase II clinical trials.
The report shows that with the commercialization of products, Cansino Biologics Inc(688185) biology has gradually established and improved its marketing system. At the same time, the company actively carries out foreign cooperation. In terms of industrialization, the company signed a joint venture contract with 3D biology and Shanghai biomedical industry investment fund and established Shangyao Cansino Biologics Inc(688185) , aiming to build a vaccine production base and enhance the company's industrialization capacity. In 2021, the recombinant covid-19 virus vaccine (adenovirus type 5 vector) was successively approved for emergency use in many countries overseas. While selling covid-19 vaccine overseas, the company also transferred the technology for the production of finished covid-19 vaccine to Mexico, Pakistan and Malaysia, helping it build its domestic covid-19 vaccine production capacity and play a demonstration effect. Through covid-19 vaccine export, the company has accumulated valuable overseas access experience and deepened its ties with local government and enterprises, which is conducive to the implementation of international development strategy.
